title: Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
abstract: OBJECTIVE
  We developed a method to suspend cisplatin in lipiodol (lipiodol-cisplatin suspension) for treating hapatocellular carcinoma. We evaluated the results of the long-term follow-up of lipiodol-cisplatin suspension therapy and the augmentation of its anti-cancer effect when in combination with transcatheter arterial embolization.
  
  
  METHODS
  Hepatic arterial injection chemotherapy with lipiodol-cisplatin suspension was performed in 239 patients with hepatocellular carcinoma without distant metastases. One hundred and forty-three patients treated with lipiodol-cisplatin suspension alone were clinically compared to 96 patients treated with lipiodol-cisplatin suspension and transcatheter arterial embolization.
  
  
  RESULTS
  Complete and partial responses were obtained in 83 cases (53.2%) in the lipiodol-cisplatin suspension alone group compared to 60 cases (62.5%) in the lipiodol-cisplatin suspension and transcatheter arterial embolization group. The survival rate of the former was 29.6% at 5 years, and of the latter was 24.2% at 5 years. The difference in survival rates between the two groups was not significant, however, in both groups excellent anti-cancer effects and prolongation of survival were seen compared to previous transcatheter arterial embolization methods.
  
  
  CONCLUSIONS
  Lipiodol-cisplatin suspension therapy has an excellent anti-cancer effect superior to previous transcatheter arterial embolization methods and prolongs the survival rate for the patients with hapatocellular carcinoma.
authors.affiliation: Third Department of Internal Medicine, Kumamoto University School of Medicine, 1-1, Honjo 1-chome, Kumamoto 860-8556, Japan. sei-c@ka2.so-net.ne.jp
authors.forename: Seishi
authors.initials: S
authors.lastname: Maeda
authors.forename: Junji
authors.initials: J
authors.lastname: Shibata
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Fujiyama
authors.forename: Motohiko
authors.initials: M
authors.lastname: Tanaka
authors.forename: Shinji
authors.initials: S
authors.lastname: Noumaru
authors.forename: Kinmochi
authors.initials: K
authors.lastname: Sato
authors.forename: Kimio
authors.initials: K
authors.lastname: Tomita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D007459:Iodized Oil; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013535:Suspensions; D007459:Iodized Oil; D002945:Cisplatin